GRAIL, Inc. (GRAL)
| Market Cap | 912.80M |
| Revenue (ttm) | 125.60M |
| Net Income (ttm) | -2.03B |
| Shares Out | 33.90M |
| EPS (ttm) | -63.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 948,713 |
| Open | 28.99 |
| Previous Close | 28.58 |
| Day's Range | 26.16 - 28.99 |
| 52-Week Range | 12.33 - 63.99 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 20.00 (-25.73%) |
| Earnings Date | May 15, 2025 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal ... [Read more]
Financial Performance
In 2024, GRAIL's revenue was $125.60 million, an increase of 34.90% compared to the previous year's $93.11 million. Losses were -$2.03 billion, 38.3% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GRAL stock is "Hold." The 12-month stock price forecast is $20.0, which is a decrease of -25.73% from the latest price.
News
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Feb. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted eq...
GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing
MENLO PARK, Calif. , Feb. 25, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, has partnered with award-winning actres...
GRAIL to Present at TD Cowen 45th Annual Health Care Conference
MENLO PARK, Calif. , Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Offi...
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Su...
GRAIL to Announce Fourth Quarter 2024 Financial Results
MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fin...
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. ...
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer scree...
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 i...
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif. , Jan. 13, 2025 /PRNewswire/ -- GRAIL, I...
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. , Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
Karen Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.
GRAIL to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. , Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif. , Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patien...
GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript
GRAIL Inc. (NASDAQ:GRAL) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - Presi...
GRAIL Reports Third Quarter 2024 Financial Results
Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif. , Nov...
GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
MENLO PARK, Calif. , Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...
GRAIL to Announce Third Quarter 2024 Financial Results
MENLO PARK, Calif. , Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fin...
GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference
Study Participants from Veteran Affairs Sites Include a Diverse Population With Toxic Exposure MENLO PARK, Calif. , Oct. 23, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose...
GRAIL Appoints Sarah Krevans to Board of Directors
MENLO PARK, Calif. , Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sar...
Stock Picks From Seeking Alpha's September 2024 New Analysts
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and...
Vieu cracks the “holy grail” of B2B sales with AI-powered business network; raises $11m as growth scales
Vieu's AI-powered Sales Graph challenges traditional social networks and CRM systems to fast-track enterprise sales pursuits. The Vieu Graph platform indexes billions of relationships and industry-spe...
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success
GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's ...
GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri
Grail's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has sig...
EU top court backs Illumina fight against EU probe into Grail deal
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.